Call for Adoption of Synchronized Biweekly Dosing of Anti-EGFR Agent Cetuximab: Implications for Patients with Metastatic Colorectal Cancer, and Squamous Cell Carcinoma of the Head and Neck

被引：2
|
作者：
Kasi, Pashtoon Murtaza [1 ]
机构：
[1] Weill Cornell Med, Meyer Canc Ctr, Englander Inst Precis Med, 1305 York Ave, New York, NY 10021 USA
来源：
ONCOLOGIST | 2022年 / 27卷 / 05期
关键词：
D O I：
10.1093/oncolo/oyac070
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：336 / 337
页数：2
相关论文
共 50 条
  • [1] Association of Cell Signalling Factors With Survival and Anti-EGFR (Cetuximab) Resistance in Head and Neck Squamous Cell Carcinoma
    Semidey-Raven, Maria Eugenia
    Alberola-Ferranti, Margarita
    Giralt, Jordi
    Hernandez-Losa, Javier
    Rodriguez-Freixinos, Victor
    Benavente, Sergio
    Moline, Teresa
    Ramon y Cajal, Santiago
    MODERN PATHOLOGY, 2015, 28 : 330A - 330A
  • [2] Association of Cell Signalling Factors With Survival and Anti-EGFR (Cetuximab) Resistance in Head and Neck Squamous Cell Carcinoma
    Eugenia Semidey-Raven, Maria
    Alberola-Ferranti, Margarita
    Giralt, Jordi
    Hernandez-Losa, Javier
    Rodriguez-Freixinos, Victor
    Benavente, Sergio
    Moline, Teresa
    Ramon y Cajal, Santiago
    LABORATORY INVESTIGATION, 2015, 95 : 330A - 330A
  • [3] Anti-EGFR Therapy: Strategies in Head and Neck Squamous Cell Carcinoma
    Oliveira-Silva, Renato J.
    de Carvalho, Ana Carolina
    Viana, Luciano de Souza
    Carvalho, Andre L.
    Reis, Rui M.
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2016, 11 (02) : 170 - 183
  • [4] Cetuximab - A review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer
    Blick, Stephanie K. A.
    Scott, Lesley J.
    DRUGS, 2007, 67 (17) : 2585 - 2607
  • [5] Tipifarnib enhances anti-EGFR activity of cetuximab in non-HRas mutated head and neck squamous cell carcinoma cancer (HNSCC)
    Shu, Lihua
    Wang, Dongsheng
    Nannapaneni, Sreenivas
    Sun, Youzhi
    Griffith, Christopher C.
    Wang, Xu
    Chen, Zhengjia
    Patel, Mihir
    El-Deiry, Mark
    Shin, Dong M.
    Chen, Zhuo G.
    Saba, Nabil F.
    ORAL ONCOLOGY, 2021, 122
  • [6] Efficacy and safety of a novel anti-EGFR ADC MRG003 in recurrent or metastatic squamous cell carcinoma of the head and neck patients
    Xue, L.
    Han, Y.
    Zhang, Q.
    Li, X.
    Fang, M.
    Zhong, L.
    Wang, S.
    Liu, Y.
    Zhang, S.
    Guo, Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S590 - S590
  • [7] Anti-EGFR (cetuximab) combined with irinotecan for treatment of elderly patients with metastatic colorectal cancer (mCRC)
    S. Abdelwahab
    A. Azmy
    H. Abdel-aziz
    H. Salim
    A. Mahmoud
    Journal of Cancer Research and Clinical Oncology, 2012, 138 : 1487 - 1492
  • [8] Anti-EGFR (cetuximab) combined with irinotecan for treatment of elderly patients with metastatic colorectal cancer (mCRC)
    Abdelwahab, S.
    Azmy, A.
    Abdel-aziz, H.
    Salim, H.
    Mahmoud, A.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2012, 138 (09) : 1487 - 1492
  • [9] Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck
    Campbell, Nicholas P.
    Hensing, Thomas A.
    Bhayani, Mihir K.
    Shaikh, Arif Y.
    Brockstein, Bruce E.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (08) : 847 - 858
  • [10] Treatment options for patients with inoperable cutaneous squamous cell carcinoma - Experiences with the anti-EGFR Antibodies Cetuximab
    Alter, M.
    Krengel, S.
    Gutzmer, R.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2011, 9 (09): : 756 - 756
12345